06:11:52 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-05-12 Ordinarie utdelning ATANA 0.00 SEK
2025-05-09 Kvartalsrapport 2025-Q1
2025-05-09 Årsstämma 2025
2025-02-21 Bokslutskommuniké 2024
2024-11-22 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-05-03 Kvartalsrapport 2024-Q1
2024-05-03 Årsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-10-27 Kvartalsrapport 2023-Q3
2023-08-18 Kvartalsrapport 2023-Q2
2023-05-08 Ordinarie utdelning ATANA 0.00 SEK
2023-05-05 Kvartalsrapport 2023-Q1
2023-05-05 Årsstämma 2023
2023-02-24 Bokslutskommuniké 2022
2022-12-07 Extra Bolagsstämma 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-09 Ordinarie utdelning ATANA 0.00 SEK
2022-05-06 Kvartalsrapport 2022-Q1
2022-05-06 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-10 Ordinarie utdelning ATANA 0.00 SEK
2021-05-07 Kvartalsrapport 2021-Q1
2021-05-07 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-11-09 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-11 Ordinarie utdelning ATANA 0.00 SEK
2020-05-08 Kvartalsrapport 2020-Q1
2020-05-08 Årsstämma 2020
2020-02-24 Bokslutskommuniké 2019
2019-11-29 Kvartalsrapport 2019-Q3
2019-08-09 Extra Bolagsstämma 2019
2019-08-07 Kvartalsrapport 2019-Q2
2019-05-08 Ordinarie utdelning ATANA 0.00 SEK
2019-05-07 Kvartalsrapport 2019-Q1
2019-04-05 Årsstämma 2019
2019-02-26 Bokslutskommuniké 2018
2018-05-08 Ordinarie utdelning ATANA 0.00 SEK
2018-05-07 Årsstämma 2018
2018-02-22 Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriLäkemedel & Handel
Attana bedriver forskning och utveckling av läkemedel. Bolaget specialiserar sig inom biologisk interaktionskarakterisering, som används för analys i utvecklandet av nya läkemedel. Bolagets patenterade lösningar används vid studerandet av bindningsegenskaper och makrostrukturer i celler, proteiner, virus och bakterier. Verksamhet återfinns främst inom Norden och Europa. Bolaget grundades under 2002 och har sitt huvudkontor i Stockholm.
2023-09-26 11:33:39

In a new article published in Frontiers in Veterinary Science (https://www.frontiersin.org/articles/10.3389/fvets.2023.1243853/full), the company Alertix Veterinary Diagnostics AB, in collaboration with several groups at the Swedish University of Agricultural Sciences, has published results for a diagnostic test for dogs having cancer. In 2019-2020, Attana performed contract research projects to select the optimal antibodies for this diagnostic test. The article states that the Alertix test has a higher sensitivity than the tests available on the market. The kinetics of the antibody interactions are in accordance with Attana's criteria for diagnostics, i.e. fast on-rate and slow off-rate.

For Attana, the article is important as it is an example of the generic applicability of Attana's technology in diagnostics and immunology. It demonstrates the importance of antibody interaction kinetics for the accuracy of the assays, in the same way as e.g. the previous articles from National University of Singapore on Hepatitis (https://news.cision.com/attana/r/new-publication-where-attana-technology-has-been-applied-for-lead-candidate-selection-of-a-new-antib,c3654657) and Tuberculosis. (https://news.cision.com/attana/r/new-publication-from-national-university-of-singapore-using-attana-technology-to-study-immune-respon,c3830773) It is in line with the larger project that Attana is part of together with Linnaeus University (https://news.cision.com/attana/r/the-swedish-knowledge-foundation-has-granted-sek-12-million-to-a-project-concerning-individual-immun,c3825152).

The results of the clinical trial demonstrate that more information than just affinity is necessary to select the optimal antibodies. A decisive factor to ensure a good protection is through the kinetics of the association rate of the antibodies to the biomarker. In this study the rate of the detecting antibodies is 3x105 and 5x105Mol/s respectively. It is at the slow range of being strong neutralizing IgG antibodies for immunity, but sufficient in a diagnostic kit as a higher concentration of the capturing antibody can be added. This means that the antibodies, in competition with other potential binders in the blood sample, interact with the biomarker faster and thus increase sensitivity and accuracy. The slow off-rate allows detection performance to be maintained to the secondary detection antibody used in ELISA methods.

According to the article, the Alertix test, Canine TK1 ELISA, has a significantly higher ability to differentiate dogs with T-Cell lymphoma compared to dogs with B-cell lymphoma than existing TK1 tests. It shows that the Aletrix test can work both for diagnosis and monitoring of dogs with lymphoma.

In the picture, the schematical displays the specific and non-specific interactions that can come up in blood tests. It is important both for diagnostic accuracy and for good immunity that the black specific curve is significantly better than the orange non-specific curve.

[En bild som visar text, skärmbild, diagram, design

Automatiskt genererad beskrivning]